Opioid-Induced Constipation - Epidemiology Forecast to 2027

Opioid-Induced Constipation - Epidemiology Forecast to 2027

  • January 2018 •
  • 50 pages •
  • Report ID: 5299604
DelveInsight’s "Opioid-Induced Constipation - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Opioid-Induced Constipation epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Opioid-Induced Constipation Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Opioid-Induced Constipation in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Opioid-Induced Constipation outlook. It also includes the explanation of changing trends of epidemiology outlining the Opioid-Induced Constipation scenario.

Opioid-Induced Constipation Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Opioid-Induced Constipation thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Opioid-Induced Constipation explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Opioid-Induced Constipation Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Opioid-Induced Constipation

Key assessments
• Patient Segmentation in Opioid-Induced Constipation
• Opioid-Induced Constipation Risk & Burden
• Factors driving growth in a specific Opioid-Induced Constipation patient population
Country=France Industry=OTC ParentIndustry=LifeSciences Date=201801 Publisher=DelveInsight Price=3000